17:50 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD)...
22:03 , May 10, 2018 |  BC Extra  |  Preclinical News

‘Nanosweepers’ could degrade beta amyloid to treat Alzheimer’s

Researchers at Beijing’s National Center for Nanoscience and Technology and colleagues published a paper in...
17:36 , May 4, 2018 |  BC Week In Review  |  Clinical News

Merck's verubecestat reduces beta amyloid levels but fails to improve cognition, function

Data published in the...
17:11 , Feb 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cell-free assays; plasma markers A composite measure of Aβ 40 , Aβ 42 and APP 669-711 levels in plasma that determines the brain burden of β amyloid could help stratify AD and MCI patients...
22:50 , Feb 2, 2018 |  BC Extra  |  Preclinical News

Plasma biomarker may aid AD diagnosis

In a study published in...
20:54 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Mouse studies suggest antisense oligonucleotides (ASOs) targeting the APOE variant APOE4 could help treat AD. In a mouse model of AD, intracerebroventricular injection of an ASO targeting APOE4 decreased β amyloid...
15:34 , Apr 26, 2017 |  BC Extra  |  Clinical News

Alzheon identifies MOA for AD candidate

In a paper published in...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
04:28 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

PF-06648671: Ph I data

A double-blind, placebo-controlled, Belgian Phase I trial in 92 healthy volunteers showed that single doses of 150 and 300 mg oral PF-06648671 and once-daily doses of 4-200 mg oral PF-06648671 for 14 days were well...
03:37 , Dec 17, 2016 |  BioCentury  |  Product Development

Not dead yet

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc. ’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for...